IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences enrolled the first patient in a Phase 1/2 clinical trial evaluating IDE892 in combination with IDE397 for MTAP-deleted solid tumors, focusing on pancreatic and non-small cell lung cancer. The company highlighted IDE892's potential best-in-class properties, including a 1,400-fold selective binding ratio and favorable drug-like characteristics, noting that monotherapy dose escalation has cleared multiple cohorts without reaching the maximum tolerated dose.
Key figures
- Drug Name
- IDE892
- Phase Of Trial
- Phase 1/2
- Cyp3a4 ic50
- >45 micromolar
- Selectivity ratio
- 1,400-fold
- Mtap deletion nsclc
- 15-20%
- Mtap deletion pancreatic
- up to 40%
- Mtap deletion solid tumors
- 15%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.